CD1d1 displayed on cell size beads identifies and enriches an NK cell population negatively regulated by CD1d1.
NK cells destroy microbe-infected cells while sparing healthy cells, and are controlled, in part, by inhibitory receptors specific for class I Ag-presenting molecules. CD1d1, a beta(2)-microglobulin-associated class I-like molecule, binds glycolipids and stimulates NKT cells. We previously demonstrated that target cell lysis by IL-2-activated mouse NK cells is inhibited by target cell expression of CD1d1, suggesting that IL-2-activated NK cells may express a CD1d1-specific inhibitory receptor. We now report that a significant subset of mouse IL-2-activated NK cells specifically binds cell size beads displaying either naturally expressed or recombinant CD1d1. In contrast, although tetramers of soluble recombinant CD1d1 loaded with alpha-galactosylceramide identify NKT cells, binding of this reagent to resting or IL-2-activated NK cells was undetectable, even with activated NK cells sorted with CD1d1 beads. Cytotoxicity by the CD1d1 bead-separated NK subset was strongly inhibited by CD1d1, compared with the NK cell subset not bound to CD1d1 beads. An Ab that blocks NKT cell recognition of CD1d1 also reverses CD1d1 inhibition of NK lysis, suggesting that TCRs of NKT cells and NK inhibitory receptor(s) may interact with a similar site on CD1d1. These results provide direct evidence for a physical interaction of NK cells with CD1d1, mediated by a functional, CD1d1-specific low-affinity inhibitory NK receptor. Display of ligands on cell size beads to maximize multivalent interaction may offer an alternative approach to examine NK cell receptor-ligand interactions, particularly those of lower expression and/or lower affinity/avidity that may go undetected using tetrameric reagents.
Huang
Michael M S
MM
Department of Medical Microbiology and Immunology, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Borszcz
Peter
P
Sidobre
Stephane
S
Kronenberg
Mitchell
M
Kane
Kevin P
KP
D000818:Animals; D019138:Antibodies, Blocking / Q000494:pharmacology; D018949:Antigens, CD1 / Q000096:biosynthesis / Q000276:immunology / Q000378:metabolism* / Q000502:physiology*; D055610:Antigens, CD1d; D002450:Cell Communication / Q000276:immunology; D045744:Cell Line, Tumor; D048429:Cell Size; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic / Q000276:immunology*; D015536:Down-Regulation / Q000276:immunology*; D005260:Female; D005699:Galactosylceramides / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000166:cytology / Q000276:immunology* / Q000378:metabolism*; D008213:Lymphocyte Activation / Q000276:immunology; D016131:Lymphocyte Subsets / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008863:Microspheres; D011485:Protein Binding / Q000276:immunology; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000502:physiology; D054340:Receptors, KIR; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism
D019138:Antibodies, Blocking; D018949:Antigens, CD1; D055610:Antigens, CD1d; D005699:Galactosylceramides; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D011971:Receptors, Immunologic; D054340:Receptors, KIR